The FDA granted fast track designation to SAR446597, an intravitreal gene therapy for the treatment of geographic atrophy due to age-related macular degeneration, according to a press release from ...

The US Food and Drug Administration (FDA) recently granted fast track designation to Sanofi’s SAR446597 for the treatment of geographic atrophy (GA). 1 ...

Sanofi SNY has announced that the FDA has granted a fast-track designation to its one-time intravitreal gene therapy, SAR446597, for the treatment of geographic atrophy (GA) due to age-related macular ...

Sanofi said SAR446597, its treatment for geographic atrophy due to age-related macular degeneration, was granted fast-track designation by the Food and Drug Administration. The French drugmaker said ...

Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast The report provides a detail ...

Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration <li /> Designat ...

The field of gerontology is witnessing a significant demographic transition, as the global population of individuals aged 65 ...